Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference
RANCHO CUCAMONGA, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi,
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
RANCHO CUCAMONGA, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi,
View HTML
Toggle Summary Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary
RANCHO CUCAMONGA, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). As part of the restructuring, Amphastar will buyback 26% of ANP’s equity
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021
Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021 RANCHO CUCAMONGA, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2021.
View HTML
Toggle Summary Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection
RANCHO CUCAMONGA, Calif., May 03, 2021 (GLOBE NEWSWIRE) --  Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet ®
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021
RANCHO CUCAMONGA, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2021 ended March 31, 2021, after the market closes on Thursday, May 6th, 2021, and will hold a conference call to
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive
View HTML
Toggle Summary Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection
RANCHO CUCAMONGA, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Dextrose injection 50% in the 50 mL Luer-Jet ® Prefilled
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020
Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 RANCHO CUCAMONGA, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended December 31,
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021
RANCHO CUCAMONGA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December 31, 2020, after the market closes on Monday, March 15th, 2021, and will hold a conference call to
View HTML

 

Copyright ©2021 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States